Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
August 5, 2021 7:00 AM EDTGvoke® prescription volume up 32% versus prior quarter
Gvoke unit sales to wholesalers and other direct customers up 36% versus prior quarter
Gvoke quarterly net sales up 10% to $8.8 million versus prior quarter
Strong cash position of $116 million
FDA approved Gvoke 1mg shelf-life extension to 30 months
EIH program to move forward in early 2022 with a Phase 2 study in broader patient populations
Proposed acquisition of Strongbridge Biopharma plc on track to close early... More
